Abstract
Introduction: The aim of the study was to systematically assess the efficacy and safety of tumor necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i), and Janus kinase inhibitors (JAKi) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods: A systematic literature search was conducted in PubMed, Embase, Web of Science, the Cochrane Register of Clinical Trials, and Scopus to find randomized controlled trials in patients with nr-axSpA published until June 2023. Stata 17.0 software and Review Manager 5.4 software were used for data analysis. The results for binary and continuous variables were expressed as the values of odds ratio and mean difference and their 95% confidence interval, respectively. Results: For Assessment of SpondyloArthritis International Society Response Criteria for 40% improvement (ASAS40), the efficacy of the 12 interventions ranked as follows: certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W) > CZP 400 mg Q4W > golimumab (GOL) > bimekizumab (BKZ) > adalimumab (ADA) > upadacitinib (UPA) > etanercept (ETN) > brodalumab (BRO) > ixekizumab (IXE) > secukinumab (SEC) 150 mg no loading (NL) > SEC 150 mg loading dose (LD) > placebo (PBO). For assessment of ASAS20, the NMA results were ranked as follows: GOL > CZP 400 mg Q4W> BKZ> ADA > UPA > CZP 200 mg Q2W > ETN > BRO > SEC 150 mg NL > SEC 150 mg LD > PBO, and GOL > ADA > PBO > UPA > SEC 150 mg NL > BKZ > IXE > SEC 150 mg LD > ETN > CZP 200 mg Q2W for adverse events. Conclusions: Most TNFi may be more effective than JAKi and IL-17i. They were all well tolerated. However, the efficacy and safety of TNFi/IL-17i/JAKi remain to be further analyzed in studies with larger sample sizes and longer follow-up times.
References
1.
Truong
SL
, McEwan
T
, Bird
P
, Lim
I
, Saad
NF
, Schachna
L
, et al. Australian consensus statements for the assessment and management of non-radiographic axial spondyloarthritis
. Rheumatol Ther
. 2022
;9
(1
):1
–24
. 2.
Navarro-Compán
V
, Sepriano
A
, El-Zorkany
B
, van der Heijde
D
. Axial spondyloarthritis
. Ann Rheum Dis
. 2021
;80
(12
):1511
–21
. 3.
Rudwaleit
M
, Sieper
J
. Referral strategies for early diagnosis of axial spondyloarthritis
. Nat Rev Rheumatol
. 2012
;8
(5
):262
–8
. 4.
Poddubnyy
D
, Brandt
H
, Vahldiek
J
, Spiller
I
, Song
IH
, Rudwaleit
M
, et al. The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic
. Ann Rheum Dis
. 2012
;71
(12
):1998
–2001
. 5.
Strand
V
, Rao
SA
, Shillington
AC
, Cifaldi
MA
, McGuire
M
, Ruderman
EM
. Prevalence of axial spondyloarthritis in United States rheumatology practices: assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis
. Arthritis Care Res Hob
. 2013
;65
(8
):1299
–306
. 6.
Ramiro
S
, Nikiphorou
E
, Sepriano
A
, Ortolan
A
, Webers
C
, Baraliakos
X
, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
. Ann Rheum Dis
. 2023
;82
(1
):19
–34
. 7.
Callhoff
J
, Sieper
J
, Weiß
A
, Zink
A
, Listing
J
. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis
. Ann Rheum Dis
. 2015
;74
(6
):1241
–8
. 8.
Corbett
M
, Soares
M
, Jhuti
G
, Rice
S
, Spackman
E
, Sideris
E
, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation
. Health Technol Assess
. 2016
;20
(9
):1
–334
. v-vi. 9.
Wang
S
, He
Q
, Shuai
Z
. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis
. Clin Rheumatol
. 2018
;37
(2
):439
–50
. 10.
Hutton
B
, Salanti
G
, Caldwell
DM
, Chaimani
A
, Schmid
CH
, Cameron
C
, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
. Ann Intern Med
. 2015
;162
(11
):777
–84
. 11.
Higgins
J
, Green
S
. Cochrane handbook for systematic reviews of interventions version 5.1.0
. The Cochrane Collaboration
; 2013
.12.
Salanti
G
. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
. Res Synth Methods
. 2012
;3
(2
):80
–97
. 13.
Salanti
G
, Ades
AE
, Ioannidis
JP
. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
. J Clin Epidemiol
. 2011
;64
(2
):163
–71
. 14.
Sieper
J
, van der Heijde
D
, Dougados
M
, Mease
PJ
, Maksymowych
WP
, Brown
MA
, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
. Ann Rheum Dis
. 2013
;72
(6
):815
–22
. 15.
Landewé
R
, Braun
J
, Deodhar
A
, Dougados
M
, Maksymowych
WP
, Mease
PJ
, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
. Ann Rheum Dis
. 2014
;73
(1
):39
–47
. 16.
Deodhar
A
, Gensler
LS
, Kay
J
, Maksymowych
WP
, Haroon
N
, Landewé
R
, et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis
. Arthritis Rheumatol
. 2019
;71
(7
):1101
–11
. 17.
Dougados
M
, van der Heijde
D
, Sieper
J
, Braun
J
, Maksymowych
WP
, Citera
G
, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial
. Arthritis Rheumatol
. 2014
;66
(8
):2091
–102
. 18.
Sieper
J
, van der Heijde
D
, Dougados
M
, Maksymowych
WP
, Scott
BB
, Boice
JA
, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis
. Arthritis Rheumatol
. 2015
;67
(10
):2702
–12
. 19.
Deodhar
A
, van der Heijde
D
, Gensler
LS
, Kim
TH
, Maksymowych
WP
, Østergaard
M
, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
. Lancet
. 2020
;395
(10217
):53
–64
. 20.
Deodhar
A
, Blanco
R
, Dokoupilová
E
, Hall
S
, Kameda
H
, Kivitz
AJ
, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study
. Arthritis Rheumatol
. 2021
;73
(1
):110
–20
. 21.
Wei
JC
, Kim
TH
, Kishimoto
M
, Ogusu
N
, Jeong
H
, Kobayashi
S
, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
. Ann Rheum Dis
. 2021
;80
(8
):1014
–21
. 22.
Deodhar
A
, Van den Bosch
F
, Poddubnyy
D
, Maksymowych
WP
, van der Heijde
D
, Kim
TH
, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
. Lancet
. 2022
;400
(10349
):369
–79
. 23.
van der Heijde
D
, Deodhar
A
, Baraliakos
X
, Brown
MA
, Dobashi
H
, Dougados
M
, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
. Ann Rheum Dis
. 2023
;82
(4
):515
–26
. 24.
Akkoç
N
, Arteaga
CH
, Auteri
SE
, Betts
M
, Fahrbach
K
, Kim
M
, et al. Comparative efficacy of biologic disease-modifying anti-rheumatic drugs for non-radiographic axial spondyloarthritis: a systematic literature review and bucher indirect comparisons
. Rheumatol Ther
. 2023
;10
(2
):307
–27
. 25.
Robinson
PC
, van der Linden
S
, Khan
MA
, Taylor
WJ
. Axial spondyloarthritis: concept, construct, classification and implications for therapy
. Nat Rev Rheumatol
. 2021
;17
(2
):109
–18
. 26.
Taams
LS
, Steel
KJA
, Srenathan
U
, Burns
LA
, Kirkham
BW
. IL-17 in the immunopathogenesis of spondyloarthritis
. Nat Rev Rheumatol
. 2018
;14
(8
):453
–66
. 27.
Deodhar
A
, Machado
PM
, Mørup
M
, Taieb
V
, Willems
D
, Orme
M
, et al. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis
. Rheumatol
. 2024
;63
(5
):1195
–205
. kead598. 28.
Tam
HKJ
, Nash
P
, Robinson
PC
. The effect of etanercept in nonradiographic axial spondyloarthritis by stratified C-reactive protein levels
. ACR Open Rheumatol
. 2021
;3
(10
):699
–706
. 29.
Braun
J
, Blanco
R
, Marzo-Ortega
H
, Gensler
LS
, van den Bosch
F
, Hall
S
, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
. Arthritis Res Ther
. 2021
;23
(1
):231
. 30.
van der Horst-Bruinsma
IE
, de Vlam
K
, Walsh
JA
, Bolce
R
, Hunter
T
, Sandoval
D
, et al. Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis through 52 Weeks: data from three phase III randomised controlled trials
. Adv Ther
. 2022
;39
(6
):2806
–19
. 31.
Robinson
PC
, Maksymowych
WP
, Gensler
LS
, Hall
S
, Rudwaleit
M
, Hoepken
B
, et al. Certolizumab pegol efficacy in patients with non-radiographic axial spondyloarthritis stratified by baseline MRI and C-reactive protein status: an analysis from the C-axSpAnd study
. ACR Open Rheumatol
. 2022
;4
(9
):794
–801
. 32.
Macaluso
FS
, Rodríguez-Lago
I
. JAK inhibition as a therapeutic strategy for inflammatory bowel disease
. Curr Drug Metab
. 2020
;21
(4
):247
–55
. 33.
van der Heijde
D
, Sieper
J
, Maksymowych
WP
, Lambert
RG
, Chen
S
, Hojnik
M
, et al. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
. Arthritis Res Ther
. 2018
;20
(1
):61
. 34.
van der Heijde
D
, Dougados
M
, Landewé
R
, Sieper
J
, Maksymowych
WP
, Rudwaleit
M
, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
. Rheumatol
. 2017
;56
(9
):1498
–509
. 35.
van der Heijde
D
, Gensler
LS
, Maksymowych
WP
, Landewé
R
, Rudwaleit
M
, Bauer
L
, et al. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
. RMD Open
. 2022
;8
(1
):e002138
. 36.
Maksymowych
WP
, Dougados
M
, van der Heijde
D
, Sieper
J
, Braun
J
, Citera
G
, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study
. Ann Rheum Dis
. 2016
;75
(7
):1328
–35
. 37.
van der Heijde
D
, Dougados
M
, Maksymowych
WP
, Bergman
G
, Curtis
SP
, Tzontcheva
A
, et al. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension
. Rheumatol
. 2022
;61
(2
):617
–27
. 38.
Kim
TH
, Kishimoto
M
, Wei
JC
, Jeong
H
, Nozaki
A
, Kobayashi
S
. Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study
. Rheumatol
. 2023
;62
(5
):1851
–9
. 39.
Baraliakos
X
, Deodhar
A
, van der Heijde
D
, Magrey
M
, Maksymowych
WP
, Tomita
T
, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
. Ann Rheum Dis
. 2024
;83
:199
–213
. 40.
Gracey
E
, Yao
Y
, Green
B
, Qaiyum
Z
, Baglaenko
Y
, Lin
A
, et al. Sexual dimorphism in the Th17 signature of ankylosing spondylitis
. Arthritis Rheumatol
. 2016
;68
(3
):679
–89
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
